Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Share
Cytokinetics Inc (CYTK) Director Robert Landry sold 1,000 shares on 2026-09-11 at $74.66 per share, reducing his holdings to 9,184 shares. The company has a market cap of $10.25 billion. Over the past year, insiders have sold 78 times with no buys. GuruFocus values CYTK at $216.76, classifying it as a 'Possible Value Trap.'
How this was made
The 30-second read
Why it matters
The disclosed insider sale is a primary Form 4 filing, providing new data on insider holdings and recent activity.
Market read
The filing adds a data point for investors monitoring insider activity; the modest size limits broader market impact.
What to watch
Guru investors are adding to positions, indicating a possible divergence between insider sentiment and smart‑money views.
Background
Cytokinetics (CYTK) is a clinical‑stage biopharma focused on muscle‑function therapeutics, with a market cap of about $10.25 bn.
Ticker impact
Director Robert Landry sold 1,000 shares on 2026-09-11, the first public disclosure of this insider transaction.
Possible short-term pressure on the stock, limited to a few percent at most.
Insider sales often weigh on sentiment, yet the transaction size ($~75k) is small and may not move a $10B market cap significantly.
Market effects
Minimal impact on the broader biotech sector; insider sell trends are company‑specific.
No regional effect beyond the company's share price.
Limited to investors tracking CYTK.
Counterpoint
Despite insider selling, the stock trades at a large discount to its GF Value, suggesting potential upside if fundamentals hold.
Key entities
- DirectorRobert Landry
Insider who sold 1,000 shares.
